|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A new criterion of coal burst proneness based on the residual elastic energy index显示文摘To evaluate the coal burst proneness more precisely,a new energy criterion namely the residual elastic energy index was proposed.This study begins by performing the single-cyclic loading-unloading uniaxial compression tests with five pre-peak unloading stress levels to explore the energy storage characteristics of coal.Five types of coals from different mines were tested,and the instantaneous destruction process of the coal specimens under compression loading was recorded using a high speed camera.The results showed a linear relationship between the elastic strain energy density and input energy density,which confirms the linear energy storage law of coal.Based on this linear energy storage law,the peak elastic strain energy density of each coal specimen was obtained precisely.Subsequently,a new energy criterion of coal burst proneness was established,which was called the residual elastic energy index(defined as the difference between the peak elastic strain energy density and post peak failure energy density).Considering the destruction process and actual failure characteristics of coal specimens,the accuracy of evaluating coal burst proneness based on the residual elastic energy index was examined.The results indicated that the residual elastic energy index enables reliable and precise evaluations of the coal burst proneness. | Fengqiang Gong Yunliang Wang Zhiguo Wang Junfeng Pan Song Luo | 2021 | International Journal of Mining Science and Technology2021，31，4： | 16 |
| 2 | Effects of Dietary Corn Gluten Meal on Growth Performance and Protein Metabolism in Relation to IGF-I and TOR Gene Expression of Juvenile Cobia (Rachycentron canadum)显示文摘A growth experiment was conducted on cobia(Rachycentron canadum,initial weight 108.2 g ± 3.0 g) to investigate the effects of dietary corn gluten meal(CGM) levels on the fish growth,whole body composition and protein metabolism in relation to specific gene expression.Five isonitrogenous(crude protein 45%) and isoenergetic(gross energy 20 kJ g 1) practical diets were formulated by replacing 0%(the control),17.5%,35.0%,52.5%,and 70.0% of fish meal(FM) protein with CGM protein.No significant differences were observed in the survival,feed intake(FI),specific growth rate(SGR),feed efficiency(FE) and protein productive value(PPV) among fish fed diets with 0%,17.5%,35.0%,and 52.5% of CGM protein.However,these indices were significantly lower in fish fed the diet with 70.0% of CGM protein than those in fish fed the control diet(P < 0.05).The whole-body crude protein and lipid contents were significantly lower while the whole-body moisture content was significantly higher in fish fed the diet with 70.0% of CGM protein compared with the control group(P < 0.05).When 70.0% of FM protein was replaced by CGM,plasma total protein and cholesterol contents were significantly lower than those in the control group(P < 0.05).Fish fed the diet with 70.0% of CGM protein had significantly lower hepatic insulin-like growth factor I(IGF-I) expression levels than those in the control group(P < 0.05).However,no significant differences were observed in hepatic target of rapamycin(TOR),dorsal muscle IGF-I and TOR expression levels among dietary treatments.Results of the present study indicated that 52.5% of FM protein could be replaced by CGM in the diets without significant influences on the growth,feed utilization and protein metabolism of juvenile cobia.The present results might be useful for developing cost effective and sustainable cobia dietary formulations. | LUO Yiwen AI Qinghui MAI Kangsen ZHANG Wenbing XU Wei ZHANG Yanjiao LIUFU Zhiguo | 2013 | Journal of Ocean University of China2013，12，3： | 10 |
| 3 | Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer:A phase II open-label clinical study显示文摘Objective: The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel(nab-paclitaxel) plus cisplatin vs. gemcitabine plus cisplatin in patients with advanced non-small-cell lung cancer(NSCLC).Methods: A total of 84 participants received either 100 mg/m^2 nab-paclitaxel each week on d 1, 8 and 15 of a 28 day cycle, as well as cisplatin 75 mg/m^2 on d 1 every three weeks(nab-TP arm); or gemcitabine 1,000 mg/m^2 on d 1 and 8, plus cisplatin 75 mg/m^2 on d 1 every three weeks(GP arm). The primary end point was progression-free survival(PFS). The secondary end points were overall response rate(ORR) and overall survival(OS).Results: According to our analysis, the median PFS was 4.8 months for the nab-TP arm vs. 5.2 months for the GP arm(P=0.55). Analysis showed the median OS was 14.6 months for participants who were in the nab-TP arm vs. 15.1 months for those in the GP arm(P=0.94). Besides, nab-TP showed OS advantages over GP in patients harboring epidermal growth factor receptor(EGFR) mutation(26.7 vs. 15.3 months, P=0.046) and patients with a performance status of 0(23.5 vs. 14.7 months, P=0.020). It was found that incidences of drug-related grade 3 or 4 toxicities were comparable between the two treatment arms.Conclusions: Therefore, it can be seen that weekly nab-TP treatment has a similar efficacy and tolerability to GP treatment for patients who are undergoing their first-line treatment for NSCLC. It could be that survival differences among platinum doublets in the context of both EGFR mutation and performance status have the potential to be the basis for our further clinical trials. | Shanshan Qin Hui Yu Xianghua Wu Zhiguo Luo Huijie Wang Si Sun Mingzhu Huang Jia Jin Zhonghua Tao Jie Qiao Yu Feng Jialei Wang Jianhua Chang | 2019 | Chinese Journal of Cancer Research2019，31，2： | 9 |
| 4 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 5 | Individualized Design of the Ventilator Mask based on the Residual Concentration of CO2显示文摘OSAHS(Obstructive Sleep Apnea Hypopnea Syndrome)is a respiratory disease mainly characterized by limited and repeated pauses of breathing in sleep.Currently,the optimal treatment is to apply CPAP(Continuous Positive Airway Pressure)ventilation on the upper airway of the patient through a household respiratory machine.However,if the ventilator mask is designed improperly,it might cause the residue and repeated inhalation of CO2,which will exert an adverse impact on the therapeutic effect.Present research numerically analyzed the CO2 transportation inside a commercial ventilator mask(Mirage SoftGel,ResMed,Australia)based on the reconstructed 3D numerical model of a volunteer's face and performed the improved design of the ventilator mask in terms of the CO2 residual concentration below the nostrils.The fluid dynamic analyses showed that at the end time of expiratory,the CO2 residual concentration below the nostrils is close to 4%.To improve the therapeutic effect,we changed the position of the exhaust holes and found that by moving the exhaust holes to the bottom of the ventilator mask,the CO2 residual concentration below the nostrils would be reduced to no more than 1%.This study established a near physiological computational model and provided a new method for the individualized design of the commercial ventilator mask. | Zhiguo Zhang Zhenxiao Li Yifei Zhang Zhenze Wang Minzhou Luo | 2018 | Computer Modeling in Engineering & Sciences2018，，11： | 3 |
| 6 | TMF-IMPAD Spectrometer | Zhu, Shengyun Luo, Qi Guo, Zhenghui Zheng, Shengnan Fan, Zhiguo Li, Anli Li, Guangsheng Wen, Shuxian Dai, Zhengyu Liu, Xiangan Wu, Xiaoguang | 1996 | Chinese journal of nuclear physics1996，，3： | 2 |
| 7 | Current management of chemotherapy-induced neutropenia in adults:key points and new challenges显示文摘Chemotherapy-induced neutropenia(CIN)is a potentially fatal and common complication in myelosuppressive chemotherapy.The timing and grade of CIN may play prognostic and predictive roles in cancer therapy.CIN is associated with older age,poor functional and nutritional status,the presence of significant comorbidities,the type of cancer,previous chemotherapy cycles,the stage of the disease,specific chemotherapy regimens,and combined therapies.There are many key points and new challenges in the management of CIN in adults including:(1)Genetic risk factors to evaluate the patient’s risk for CIN remain unclear.However,these risk factors urgently need to be identified.(2)Febrile neutropenia(FN)remains one of the most common reasons for oncological emergency.No consensus nomogram for FN risk assessment has been established.(3)Different assessment tools[e.g.,Multinational Association for Supportive Care in Cancer(MASCC),the Clinical Index of Stable Febrile Neutropenia(CISNE)score model,and other tools]have been suggested to help stratify the risk of complications in patients with FN.However,current tools have limitations.The CISNE score model is useful to support decision-making,especially for patients with stable FN.(4)There are still some challenges,including the benefits of granulocyte colony stimulating factor treatment and the optimal antibiotic regimen in emergency management of FN.In view of the current reports,our group discusses the key points,new challenges,and management of CIN. | Committee of Neoplastic Supportive-Care(CONS),China Anti-Cancer Association Committee of Clinical Chemotherapy,China Anti-Cancer Association Yi Ba Yuankai Shi Wenqi Jiang Jifeng Feng Ying Cheng Li Xiao Qingyuan Zhang Wensheng Qiu Binghe Xu Ruihua Xu Bo Shen Zhiguo Luo Xiaodong Xie Jianhua Chang Mengzhao Wang Yufu Li Yuerong Shuang Zuoxing Niu Bo Liu Jun Zhang Li Zhang Herui Yao Conghua Xie Huiqiang Huang Wangjun Liao Gongyan Chen Xiaotian Zhang Hanxiang An Yanhong Deng Ping Gong Jianping Xiong Qinghua Yao Xin An Cheng Chen Yanxia Shi Jialei Wang Xiaohua Wang Zhiqiang Wang Puyuan Xing Sheng Yang Chenfei Zhou | 2020 | Cancer Biology & Medicine2020，17，4： | 2 |
| 8 | OSCILLATION OF DELAY DIFFERENTIAL EQUATIONS WITH PIECEWISE CONSTANT ARGUMENT显示文摘The delay differential equation with piecewise constant argument x′(t)+a(t)x(t)+ b(t) x([t-k])=0 is considered,where a(t) and b(t) are continuous functions on [-k,∞),b(t)≥0,k is a positive integer and [·] denotes the greatest integer function.Some new oscillation and nonoscillation conditions are obtained. | Luo Zhiguo Shen JianhuaDept. of Math., Hunan Normal Univ., Changsha 410081. E mail: luozg@mail. hunnu.edu.cn | 2000 | Applied Mathematics(A Journal of Chinese Universities)2000，15，4： | 2 |
| 9 | Preparation of Incompact Strontium Aluminate Phosphors显示文摘The incompact long afterglow pigment SrAl2O4: Eu, Dy was synthesized by ceramics technology.The agglomerated starting raw material had little effect on the synthesis of SrA12O4 matrix through solid-state reaction method,but the shrinkage and densification was retarded greatly by the agglomerated powder by the formation of large and extensive pore network.The sintering mechanism is surface diffusion ( without flux B2O3 ) and grain boundary diffusion (with B2O3 as flux)respectively, and the as-prepared long afterglow pigment glows in the dark for over 4000 min. | Luo Xixian Xiao Zhiguo Xia Wei Cao Wanghe | 2004 | Journal of Rare Earths2004，22，z1： | 1 |
| 10 | Impulsive stabilization of functional differential equations with infinite delays 显示文摘 | Luo Zhiguo Shen Jianhua | 2003 | Appl Math Letters2003，16，： | 1 |
| 11 | Stability and boundedness for impulsive functional differential equations with infinite delays 显示文摘 | Luo Zhiguo Shen Jianhua | 2001 | Nonlinear Analysis2001，46，： | 1 |
| 12 | Unconventional Hamilton-type variational principles for nonlinear coupled thermoelastodynamics显示文摘 | En Luo Junshang Kuang Weijiang Huang Zhiguo Luo | 2002 | Science in China Series A: Mathematics2002，，6： | 1 |
| 13 | Magnetic retrieval of graphene: extraction of sulfonamide antibiotics from environmental water samples显示文摘 | LUO Yanbo SHI Zhiguo GAO Qiang | 2011 | J Chromatogr A2011，1218，10： | 1 |
| 14 | Stability of impulsive functional differential equations via the Liapunov functional 显示文摘 | Luo Zhiguo Shen Jianhua | 2008 | Appl Math Lett2008，10，： | 1 |
| 15 | Stability of impulsive functional differential equations via the Liapunov functional 显示文摘 | Luo Zhiguo Shen Jianhua | 2008 | Appl Math Lett2008，03，： | 1 |
| 16 | Impulsive stabilization of functional differential equations with infinite delay显示文摘 | Shen Jianhua | 2003 | Applied Mathematics Letters2003，16，5： | 1 |
| 17 | Some Oscillation Criteria for Difference Equations显示文摘 | ZHIGUO LUO | 2000 | Computers and Mathematics with Appliccations2000，，： | 1 |
| 18 | Downregulation of CD147 by chitooligosaccharide inhibits MMP?2 expressionand suppresses the metastatic potential of human gastric cancer显示文摘 | Zhiguo Luo Xiaoxia Dong Qing Ke Qiwen Duan Li Shen | 2014 | Oncology Letters2014，，1： | 1 |
| 19 | Cloud com- puting: an overview显示文摘 | Qian Ling Luo Zhiguo Du Yujian | 2009 | Lecture Notes in Computer Science2009，5931，1： | 1 |
| 20 | 显示文摘 | Luo Xixian Cao Wanghe Xiao Zhiguo | 2006 | Journal of Alloys and Compounds2006，416，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员